Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug RSC-1255 takes on Hard-to-Treat cancers

NCT ID NCT04678648

Recruiting now Disease control Sponsor: RasCal Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and then checking for early signs of effectiveness. About 134 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RSC-1255 (an experimental drug taken orally) alone or with hydroxychloroquine
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors or may cause side effects. It is too soon to know if it will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colon carcinoma colonic neoplasm Disease Progression glioblastoma lung cancer lung neoplasm malignant pancreatic neoplasm neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT SOLID NEOPLASM COLON CANCER GLIOBLASTOMA LUNG CANCER PANCREATIC CANCER RAS MUTATION

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Sarah Cannon, SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon, SCRI Oncology Partners - Health One

    RECRUITING

    Denver, Colorado, 80218, United States

  • University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology

    RECRUITING

    Los Angeles, California, 90404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.